Антибиотики и Химиотерапия

Расширенный поиск

Молекулярные и клеточные механизмы действия финголимода

Полный текст:


Представлены данные о механизме действия, эффективности и безопасности препарата финголимод. Дальнейшее изучение молекулярных, биохимических и клеточных механизмов действия фармакологических регуляторов трансдукции сигналов фосфолипидных медиаторов является важной основой для создания новых иммуномодуляторов и противоопухолевых средств.

Об авторе

А. В. Никитин


Список литературы

1. NDA 02257-FDA approved labeling text for Gilenya (fiingolimod) capsules / September 21, 2010.

2. Billich A., Bonmancin F., Devay P. et al. Phosphorilation of the immunomodulatory drug FTY720 by sphingosine kinase. J Biol Chem 2003; 278: 47408-47415.

3. Paugh S.W., Payne S.G., Barbour S.E. et al. The immunosupressant FTY720 is phosphorilated by sphingosine kinase type 2. FEBS Lett 2003; 554: 189-193.

4. Spiegel S., Milstein S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Res Mol Cell Biol 2003; 4: 397-407.

5. Ishii I., Fukushima N., Ye X., Chung J. Lysophospholipid receptors: signalling and biology. Annu Rev Biochem 2004; 73: 321-354.

6. Schwab S.R., Pereira J.P., Matloullian M. et al. Lymphocyte sequestration through S1P lyase inhibition and disruption S1P gradients. Science 2005; 309: 1735-1739.

7. Oo M.L., Thangada S., Wu M.-T. et al. Immunosupressive and anti-angiogenic sphingosine-1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation by internalized S1P1 receptors. Nat Chem Biol 2009; 5: 428-434.

8. Kappos L., Radue E.-W., O., Konnor P. et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Eng J Med 2010; 362: 387-401.

9. Cohen J.A., Barkhof F., Comi G. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Eng J Med 2010; 362: 402-415.

10. Dehmel T., Opgenoorth B., Hartung H. et al. The effect of fingolimod on peripheral blood mononuclear cell phenotypes: a prospective study (P02.122). Neurology 2012, 78 (Meeting abstracts 1): P02.122.

11. Sehr T., Hainke U., Thomas K. et al. Differential immunological changes in peripheral and CNS compartments during fingolimod therapy in MS (P02.087). Neurology 2012, 78 (Meeting abstracts 1): P02.087.

12. Darlington P., Ouamara N., Stonebridge I. et al. Fingolimod treatment in multiple sclerosis increases the ability of circulating γδ T cells to regulate pro-inflammatory Th1 and Th2 T cell responses (S31.003). Neurology 2012, 78 (Meeting abstracts 1): S31.003.

13. Cohen J.A., Chun J. Mechanisms of fingolimod’s efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011; 69: 759-777.

14. Kipp M., Amor S. FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination. Mult Scller 2012; 18: 258-262.

15. Thomas K., Sehr T., Hainke U. et al. Differential effects of natalizumab and fingolimod on the innate immune system of MS patients (P04.125). Neurology 2012, 78. (Meeting abstracts 1): P04.125.

16. Lorvik K.B., Bogen B., Corthay A. Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice. Blood 2012; 119: 2176-2177.

17. Cannon R.E., Pearle J.C., Hawkins B.T. et al. Targeting blood-brain barrier sphingolipid signalling reduces basal P-glycoprotein activity and improves drug delivery to the brain. Proc Natl Acad Sci. USA 2012; 109: 15930-15935.

18. Di Marco J.P., O'Connor P., Cohen J.A. et al. First dose effect of fingolimod: pooled safety data from two phase 3 studies (TRANSFORMS and FREEDOMS) (P830). Mult Scler 2010; 16: Suppl 10.

19. Kennedy P.C., Zhu R., Huang T. et al. Characterization of a sphingosine-1-phosphate receptor antagonist prodrug. J Pharmacol Exp Ther 2011; 338: 879-889.

Для цитирования:

Никитин А.В. Молекулярные и клеточные механизмы действия финголимода. Антибиотики и Химиотерапия. 2013;58(11-12):38-42.

For citation:

Nikitin A.V. Molecular and Cellular Mechanisms of Fingolimod Action. Antibiotics and Chemotherapy. 2013;58(11-12):38-42. (In Russ.)

Просмотров: 3

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 0235-2990 (Print)